Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SYNLOGIC, INC.SYBX · Entity 7801 | Chief Medical Officer | March 10, 2021 | March 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SYNLOGIC, INC.
Report date March 10, 2021 · Filed March 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,000 |
Reported balance
After 2021-03-10 transaction · row 1
1 source rowRow 1 · 2021-03-10 · Grant · Acquired 17,500 · Balance 39,000 F1: The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2031-03-10 | Direct | 70,000 |
Reported balance
After 2021-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-10 · Grant · Acquired 70,000 · Balance 70,000 F2: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 1, 2021, with the first installment vesting on May 1, 2021 subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date.
F2: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 1, 2021, with the first installment vesting on May 1, 2021 subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2021 Filed Mar 12, 2021 21:53 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-21-011336 · doc4.xml · derivative · entry 2 Riese Richard J. · CIK 0001786692 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-10 F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 1, 2021, with the first installment vesting on May 1, 2021 subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:53 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011336 · doc4.xml · nonDerivative · entry 1 Riese Richard J. · CIK 0001786692 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 F1 · shares: The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:00 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000899243-20-008100 · doc4.xml · derivative · entry 2 Riese Richard J. · CIK 0001786692 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2030-03-10 F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 10, 2020, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 22:00 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008100 · doc4.xml · nonDerivative · entry 1 Riese Richard J. · CIK 0001786692 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 F1 · shares: The shares of restricted stock were granted on March 10, 2020 (the "Grant Date") and will vest in four equal annual installments on each anniversary of the Grant Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 13:00 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000899243-20-000021 · doc4.xml · derivative · entry 1 Riese Richard J. · CIK 0001786692 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-12-31 F1 · derivative.exercise_date: The option will vest and become exercisable as to one-fourth (1/4) of the shares on September 16, 2020, and the remainder will vest and become exercisable at one-forty-eighth (1/48th) of the shares per month thereafter, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 20:30 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024249 · doc4.xml · nonDerivative · entry 1 Riese Richard J. · CIK 0001786692 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · shares: On September 23, 2019 (the "Grant Date"), the reporting person was granted 8,000 shares of restricted stock of the company under the company's 2015 Equity Incentive Award Plan as part of a company-wide equity grant that was made to all employees. 100% of the shares of restricted stock will vest 18 months from the Grant Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.